Reuters logo
BRIEF-Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate
October 4, 2017 / 1:33 PM / in 19 days

BRIEF-Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate

Oct 4 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate 40mg/ml and launch of generic Glatiramer Acetate 20mg/ml

* ‍Any launch by Mylan of generic version of Copaxone prior to final resolution of pending patent litigation should be considered “at-risk” launch​

* ‍Early assessment of impact of generic launches to earnings for Q4 ended Dec 31, 2017 is that it could be affected by at least $0.25 cents/share​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below